Hinda Najem
Research Subjects
Research Interests
Hinda Najem has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Amy B. Heimberger
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University , Chicago, Illinois
1 shared publication Craig M. Horbinski
Department of Neurological Surgery
1 shared publication- Crismita Dmello
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
1 shared publication - Daniel Procissi
Department of Radiology, Feinberg School of Medicine, Northwestern University Chicago, IL, USA
1 shared publication - David M. Ashley
Duke University
1 shared publication - David R. Raleigh
Department of Radiation Oncology, University of California San Francisco , San Francisco, California
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 16 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (4)
STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma model
Radiation therapy (RT) is the standard of care for glioblastoma but is not curative. Triggering the cGAS/stimulator of interferon genes (STING) pathway with potent agonists, such as 8803, exerts activity across high-grade glioma preclinical models. To determine if the combination of 8803 with RT warrants consideration in the up-front treatment setting and to clarify the underlying mechanisms of therapeutic activity, C57BL/6J mice harboring intracerebral CT-2A or QPP8v gliomas were treated with RT, intratumoral 8803, or both. The treatment with the combination resulted in 80% long-term survival in the CT-2A model but not in the radiation-resistant QPP8v model. This therapeutic effect was maintained in Sting –/– CT-2A cells, highlighting the direct role of the immune system in mediating the survival benefit. Single-cell RNA-Seq identified increased nitric oxide synthase 2 ( Nos2 ) in inflammatory tumor-associated macrophages; however, the therapeutic effect was maintained in Nos2 –/– mice. Additionally, 8803 reprogrammed the blood-brain barrier (BBB) by altering the Pecam and Cd147 pathways in endothelial cells; intracranial injection of 8803 induced bihemispheric BBB opening for up to 24 hours. Sting activation was visualized longitudinally using 3’-deoxy-3’-[ 18 F]-fluorothymidine ([ 18 F]-FLT) PET, which peaked 72–96 hours after 8803 administration. In summary, 8803 combined with RT triggers distinctive antiglioma immune reactivity, facilitates BBB opening, and warrants consideration for up-front clinical trials in glioblastoma, where treatment effects can be monitored using [ 18 F]-FLT PET imaging.
- 16 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (4)
Top Cited PapersOpen AccessSTING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma model
Radiation therapy (RT) is the standard of care for glioblastoma but is not curative. Triggering the cGAS/stimulator of interferon genes (STING) pathway with potent agonists, such as 8803, exerts activity across high-grade glioma preclinical models. To determine if the combination of 8803 with RT warrants consideration in the up-front treatment setting and to clarify the underlying mechanisms of therapeutic activity, C57BL/6J mice harboring intracerebral CT-2A or QPP8v gliomas were treated with RT, intratumoral 8803, or both. The treatment with the combination resulted in 80% long-term survival in the CT-2A model but not in the radiation-resistant QPP8v model. This therapeutic effect was maintained in Sting –/– CT-2A cells, highlighting the direct role of the immune system in mediating the survival benefit. Single-cell RNA-Seq identified increased nitric oxide synthase 2 ( Nos2 ) in inflammatory tumor-associated macrophages; however, the therapeutic effect was maintained in Nos2 –/– mice. Additionally, 8803 reprogrammed the blood-brain barrier (BBB) by altering the Pecam and Cd147 pathways in endothelial cells; intracranial injection of 8803 induced bihemispheric BBB opening for up to 24 hours. Sting activation was visualized longitudinally using 3’-deoxy-3’-[ 18 F]-fluorothymidine ([ 18 F]-FLT) PET, which peaked 72–96 hours after 8803 administration. In summary, 8803 combined with RT triggers distinctive antiglioma immune reactivity, facilitates BBB opening, and warrants consideration for up-front clinical trials in glioblastoma, where treatment effects can be monitored using [ 18 F]-FLT PET imaging.